Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01185132

Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal external beam radiotherapy, spares more normal breast and lung tissue, and may lead to improved clinical outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically confirmed disease (AJC Classification): Tis, T1, T2 (≤ 3.0 cm), N0, M0.
  • Microscopic multifocal disease is only allowed when the entire span of identified disease measures 3.0 cm or less.
  • Negative surgical margins ( ≥ 0.2 cm) after final surgery.
  • Subjects with infiltrating lobular histologies or high nuclear grade DCIS will be required to have breast MRI scanning as part of the initial staging to verify localized disease.
  • Subjects with DCIS will be included in the study only if they had an MRI prior to lumpectomy.
  • Findings on MRI scanning revealing relevant suspicion of disease outside of planned lumpectomy volume should be further evaluated by ultrasound and, if necessary biopsy, to exclude multicentric/multifocal disease.
  • Subjects with malignant calcifications on mammography will be required to have repeat mammography after surgery to ensure removal of all malignant calcifications.
  • Willing to complete additional screening requirements and meet eligibility criteria as defined in protocol Sec. 4.4.
  • Successful placement of fiducial markers for IGRT requiring nonmigrating fiducials.
  • PTV to ipsilateral breast ratio (IBR) ≤ 25 %.
  • Radiotherapy anticipated to begin within 10 weeks of lumpectomy or re-excision of margins.

Exclusion criteria

  • Pregnancy or breast-feeding.
  • Have collagen-vascular disease.
  • Inadequate surgical margins ( < 0.2 cm) after final surgery.
  • Subjects with persistent malignant/suspicious micro-calcifications.
  • Gross multifocal disease and microscopic disease greater than 3.0 cm.

Treatment and study plan

accelerated partial breast irradiation - 3D-conformal planning

Radiation

38.5 Gy, 10 fractions over 5 days

Other names: APBI, EBRT

accelerated partial breast irradiation - IMRT planning

Radiation

38.5 Gy, 10 fractions over 5 days

Other names: APBI, EBRT

Primary outcomes

  1. Prevalence of breast pain after Accelerated Partial Breast Radiotherapy (APBI)

    Time frame: 5 years

    Assessment by both treating investigators and by subjective patient outcomes questionnaires filled out at each follow-up visit

  2. Prevalence of chest wall pain after Accelerated Partial Breast Radiotherapy (APBI)

    Time frame: 2-5 years

    Assessment by both treating investigators and by subjective patient outcomes questionnaires filled out at each follow-up visit

Secondary outcomes

  1. Dosimetric comparison

    Time frame: 5-10 days

    Comparison of treatment plans and actual doses received between comparable patients treated with 3D-CRT and IMRT with regard to treatment target and normal tissue

  2. Acute skin reactions

    Time frame: 6 months

    Radiation-induced dermatitis

  3. Cosmetic outcomes after APBI

    Time frame: 2-5 years

    Assesed by both treating investigators and subjective patient questionnaires filled out at each follow-up visit

  4. Ipsilateral breast event

    Time frame: 5-15 years

    Track occurrence and patterns of local treatment failures or new primaries within the treated breast (efficacy outcome measure)

  5. Cause specific survival

    Time frame: 5-15 years

    Track survival status and the specific cause(s) of death if applicable for study participants (efficacy outcome measure)

  6. Disease free survival

    Time frame: 5-15 years

    Track breast-cancer free survival status of study participants (efficacy outcome measure)

  7. Overall survival

    Time frame: 5-15 years

    Track the overall survival status of all study participants (efficacy outcome measure)

Study contacts

Contact information is provided by the study sponsor or research team.

Charles Leonard, MD

CONTACT

303-730-4700

Rachel Lei, BS

CONTACT

[email protected]

303-418-7607

Sponsors and collaborators

Lead sponsor

Rocky Mountain Cancer Centers

Other

Registry information

Official study title

A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy

Acronym: 2009-APBI

Important dates

Study start
2009
Primary completion
2018
Study completion
2028
First posted
Aug 19, 2010
Registry last updated
Jun 26, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.